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Background/aim: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor
cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact
with programmed cell death protein 1 (PD-1), causing immunosuppression. The aim of our study is to examine the correlation between
the serum sPD-1 and sPD-L1 levels and clinicopathological characteristics in patients with nonsmall cell lung cancer. We also compared
our results with the healthy population (control group).
Materials and methods: Thirthy-seven nonsmall cell lung cancer (NSCLC) patients who were operated in our clinic were included
in our study. The control group included fifteen healthy patients. The sPD-1 and sPD-L1 levels were measured in serum samples
by using the ELISA method.
Results: The preoperative sPD-1 and sPD-L1 levels were significantly higher in the study group compared to the control group (44.12
± 22.25 pg/mL vs. 18.54 ± 6.56 pg/mL; p = 0.001 and 26.15 ± 18.03 pg/mL vs. 10.29 ± 3.08 pg/mL; p = 0.001, respectively). There was a
statistically significant decline in serum sPD-1 and sPD-L1 levels at the preoperative and postoperative 1st, 7th, and 30th days following
surgical resection (44.12 ± 22.25 pg/mL, 37.86 ± 18.02 pg/mL, 36.33 ± 18.36 pg/mL, 34.14 ± 13.71 pg/mL; p = 0.007 and 26.15 ± 18.03
pg/mL, 20.60 ± 15.50 pg/mL, 18.31 ± 14.04 pg/mL, 13.64 ± 10.60 pg/mL; p = 0.001, respectively).There was a positive correlation
between the preoperative and postoperative 30th day serum sPD-1 levels and the tumor size (p = 0.031, r = 0.352; p = 0.024, r = 0.371;
respectively). We also found a positive correlation between the preoperative and postoperative 30th day serum sPD-L1 levels and pleural
invasion (p = 0.001, p = 0.001; respectively), and the N category (p = 0.015, p = 0.013; respectively).
Conclusion: We think that sPD-1 and sPD-L1 levels may be used as a potential biomarker for lung cancer screening, prediction of the
stage, and besides to detect recurrences and/or metastases following resection in NSCLC following validation with multicenter and
larger-scale prospective trials.
Key words: Nonsmall cell lung cancer (NSCLC), soluble programmed cell death protein 1 (sPD-1), soluble programmed cell death
ligand 1 (sPD-L1), thoracic surgery

1. Introduction
Cancer is a major health problem with rapidly increasing
incidence and mortality worldwide [1]. Numerous genetic
and epigenetic changes inherent in most cancer cells
provide a large number of tumor-associated antigens that
the host immune system can recognize and distinguish
them from normal cells [2]. Both the tumor cells and the
cells in the tumor microenvironment can express large

amounts of programmed cell death-ligand 1 (PD-L1).
These PD-L1s interact with programmed cell death protein
1 (PD-1), causing immunosuppression [3]. Therefore,
the PD-1/PD-L1 pathway plays an important role in
attenuating antitumor immunity in cancers [4]. However,
not all cancer types or all cells within a cancer type express
PD-L1. It is primarily expressed in nonsmall-cell lung
cancer (NSCLC), malignant melanoma, renal cell cancer,
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stomach cancer, hepatocellular cancer, as well as various
leukemias and multiple myeloma-like diseases [5]. This
increased expression has also been shown to be associated
with poor prognosis and decreased overall survival [6].
Immune checkpoint inhibitors used for immunotherapy
have been approved for use in the treatment of many
different types of malignancies [7].
There are two distinct expression forms of many
costimulatory molecules in immune regulatory pathways,
which are membrane-bound form and soluble form.
Studies have also shown the presence of soluble forms of
PD-1 and PD-L1. Nowadays, there are increasing number
of studies showing that serum levels of soluble PD-1 and
PD-L1 (sPD-1 and sPD-L1) can be used as biomarkers
that might help diagnosis and may be used for predicting
prognosis in specific tumors [8,9,10]. This study aimed
to investigate the correlation of sPD-1 and sPD-L1 with
clinical and pathological characteristics and lymph node
metastasis by measuring their serum levels in patients
who were operated for early-stage NSCLC and besides
to compare preoperative serum sPD-1 and sPD-L1
levels with the post-resection values and with normal
population.
2. Materials and methods
2.1. Patient characteristics
This prospective study included a total of 52 patients.
Among them, 37 patients were operated for NSCLC in
the Department of Chest Surgery of Hacettepe University
Faculty of Medicine Hospital between April 2019 and
April 2020 and represented the study group. The control
group included fifteen healthy patients who were matched
with the study group. There were 30 (81%) male and 7
(19%) female patients with a mean age of 60.41 ± 10.45
years in the study group. The control group included
fifteen healthy patients without malignancy. The control
group included 10 (66.6%) male and 5 (33.3%) female
patients, with a mean age of 39.93 ± 13.25 years. Patients
with a diagnosis of secondary cancer were not included in
the study. All patients have been informed about the study
protocol and all signed a consent form. This prospective
research project was approved by the Ethics Committee
of Hacettepe University (Decision No: 2019/09-05) and
supported by Hacettepe University Scientific Research
Projects Coordination Unit. (Project Number: TTU-201918220)
2.2. Data collection
The preoperative data included age, sex, smoking
history, and comorbidities. Postoperative data were the
histopathologic type and stage of NSCLC, the presence
of lymph node involvement, and the size and invasion
characteristics of the tumor in the pathological specimen.

2.3. Collection of serum samples
Serum samples were obtained preoperatively, on
postoperative days 1, 7, and 30 in the study group and
once in the control group. All serum samples were then
stored at –80 °C.
2.4. Measurement of sPD-1 and sPD-L1 levels using the
ELISA method
The sPD-1 and sPD-L1 levels were measured in serum
samples by using the enzyme-linked immunosorbent
assay (ELISA) method. Human PD-L1 ELISA kit
(Invitrogen Thermo Fisher Scientific Inc., USA) with a
detection limit of 0.6 pg/mL and human PD-1 ELISA
kit (Invitrogen Thermo Fisher Scientific Inc., USA) with
a detection limit of 1.14 pg/mL were used in order to
measure sPD-L1 and sPD-1 levels, respectively. The tests
were performed according to manufacturer’s instructions.
2.5. Statistical analysis
Statistical analyses were done using the SPSS version
17.0 software. Histograms and the Kolmogorov–Smirnov
test were used to assess the normality distribution of
variables. Mean, standard deviation, and median values
were used to present descriptive analyses. The Mann–
Whitney U test was used for the two-group comparison
of nonnormally distributed (nonparametric) variables,
while the Kruskal–Wallis test was used for more than two
groups. Dunn’s post hoc test was used to test for multiple
comparisons between variables for further analysis. After
specifying α = 0.01 and 99% power, G-Power 3.0 software
package was used and it was determined that a sample size
of 11 subjects per group would be required. Spearman’s
correlation test was used for the analysis of correlations
among quantifiable data. Changes in preoperative,
postoperative 1-day, 7-day, and 30-day measurements
were analyzed with Friedman’s test. Results with a p-value
less than 0.05 were considered statistically significant.
3. Results
3.1. Comparison of sPD-1 and sPD-L1 levels
The study group had a statistically significantly higher
preoperative sPD-1 levels than the control group (44.12
± 22.25 pg/mL vs. 18.54 ± 6.56 pg/mL; p = 0.001).
Similarly, the study group had a statistically significantly
higher preoperative sPD-L1 levels than the control group
(26.15 ± 18.03 pg/mL vs. 10.29 ± 3.08 pg/mL; p = 0.001)
(Figure 1). The analysis of the alterations in preoperative,
postoperative 1st, 7th, and 30th day sPD-1 and sPD-L1
levels of the study group showed a statistically significant
decrease in levels of sPD-1 (p = 0.007). Similarly, there
was a statistically significant decrease in preoperative and
postoperative 1st, 7th, and 30th day sPD-L1 levels. (p =
0.001) (Table 1 and Figure 2).
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Figure 1. Comparison ofs PD-1 and sPD-L1 levels between the groups(The Mann–Whitney U Test).

3.2. Tumor size
Pathological tumor size (pT) is considered the tumor size.
There was a significant positive correlation between the
preoperative sPD-1 level and the tumor size (p = 0.031,
r = 0.352). There was no significant correlation between
the preoperative sPD-L1 level and the tumor size of the
patients. The analysis of the postoperative 30th day sPD1 levels showed a significant positive correlation with
tumor size (p = 0.024, r = 0.371). There was no significant
correlation between the postoperative 30th day sPD-L1
value and tumor size of the patients (Figure 3).
3.3. Histopathological types
The study group was divided into three groups based on
their histopathological types: adenocarcinoma, squamous
cell carcinoma, and neuroendocrine tumors. There were
17 patients with adenocarcinoma (46%), 12 patients with
squamous cell carcinoma (32%), and 8 patients with
neuroendocrine tumors (22%). There was no significant
difference in terms of preoperative sPD-1 (adenocarcinoma
45.97 ± 20.48 pg/mL, squamous cell carcinoma 49.19 ±
27.51 pg/mL, neuroendocrine tumors 32.58 ± 13.93 pg/
mL; p = 0.223) and sPD-L1 levels (adenocarcinoma 31.33 ±
22.58 pg/mL, squamous cell carcinoma 19.29 ± 8.17 pg/mL,
neuroendocrine tumors 25.44 ± 15.98 pg/mL; p = 0.184)
and postoperative 30th day sPD-1 levels (adenocarcinoma
36.79 ± 16.67pg/mL, squamous cell carcinoma 34.12 ±
7.19pg/mL, neuroendocrine tumors 28.55 ± 13.43 pg/
mL; p = 0.450) and sPD-L1 levels (adenocarcinoma 15.40
± 13.58 pg/mL, squamous cell carcinoma 10.07 ± 4.06
pg/mL, neuroendocrine tumors 15.23 ± 9.94 pg/mL; p =
0.509) among the histopathological types.
3.4. T category
The patients were classified according to the T category of
the TNM classification based on the data obtained from
the postresection pathology results. Of the patients in our
study, 17 (49%) had T1 disease, 13 (37%) had T2 disease, and
7 (14%) had T3 disease. There was a statistically significant
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correlation between the T category and preoperative sPD1 levels (p = 0.016). According to the post hoc analysis,
the mean preoperative sPD-1 level (53.28 pg/mL) of the
patients with a T2 tumor was statistically significantly
higher than the mean preoperative sPD-1 value (33.07 pg/
mL) of the patients with a T1 tumor. The analysis of the
correlation between the T categories and postoperative
30th day sPD-1 levels of the patients revealed a statistically
significant difference (p = 0.023). Post hoc analysis showed
that the mean postoperative 1st month sPD-1 level of the
patients with a T3 tumor (43.51 pg/mL) was statistically
higher than the mean postoperative 1st month sPD-1 level
of the patients with a T1 tumor (27.78 pg/mL). There was
no correlation between the T category and sPD-L1 levels
of the patients.
3.5. N category
The patients were classified according to the N (lymph
node) category based on the data obtained from the
postsurgical resection pathology results. There were 31
patients (84%) with N0 disease and 6 patients (16%) with
N1 disease. There was a positive correlation between the
N category and preoperative sPD-L1 levels. Preoperative
sPD-L1 levels significantly increased as the N category
increased (p = 0.015). However, there was no correlation
between the N category and the preoperative sPD-1 levels
of the patients. The postoperative 30th day sPD-L1 levels
significantly rose in higher N categories (p = 0.013),
whereas there was no correlation between the N categories
and postoperative 30th day sPD-1 levels.
3.6. Pleural invasion
The patients with pleural invasion had a significantly higher
presurgical sPD-L1 levels than those of without invasion (p
= 0.001). Similarly, the patients with pleural invasion had
significantly higher postoperative 30th day sPD-L1 levels
than those of without invasion (p = 0.001). However, no
statistically significant correlation was detected between
sPD-1 levels and pleural invasion (Table 2).
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Table 1. sPD-1 and sPD-L1 levels of the study group.

sPD-1 levels
(pg/mL)

n

Mean

Median

SD

Preoperative

37

44.12

38.79

22.25

Postoperative 1st day

37

37.86

32.65

18.02

Postoperative 7th day

37

36.33

31.07

18.36

Postoperative 30th day

37

34.14

33.64

13.71

Preoperative

37

26.15

18.31

18.03

37

20.60

15.65

15.50

37

18.31

12.91

14.05

37

13.64

9.48

10.60

Postoperative 1st day
sPD-L1
levels(pg/mL) Postoperative 7th day
Postoperative 30th day

p

Post
hoc

0.007*

1–2
1–3
1–4

0.001*

1–2
1–3
1–4
2–4
3–4

Friedman two-way analysis of variance
SD: standard deviation
*: statistically significant

Figure 2. Decline of thesPD-1 and sPD-L1 levels of
 the study group within the 1st month following surgery
(Friedman two-way analysis of variance).

Figure 3. Correlation between the preoperative and postoperative 30th day sPD-1 levels and the tumor size (Spearman’s
rho correlation test).
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Table 2. Pre- and postoperative sPD-1 and sPD-L1 levels among subgroups.
Median
T1 (n = 17)
T2 (n = 13)
T3 (n = 7)
N0 (n = 31)
N1 (n = 6)
T1 (n = 17)
T2 (n = 13)
T3 (n = 7)
N0 (n = 31)
N1 (n = 6)
Pleural invasion Pleural invasion +
Pleural invasion Pleural invasion +

SD

p-value

Median

SD

p-value

Preoperative sPD-1 levels (pg/mL)

Preoperative sPD-L1 levels (pg/mL)

33.07
±10.03
0.016 b*
53.28
±29.77
(T1-T2)c
46.78
±16.02
38.79
±21.71
0.510a
46.74
±26.75
Postoperative 30th day sPD-1 levels (pg/mL)
27.78
±11.92
0.023 b *
40.65
±14.40
(T1-T3) c
43.51
±11.03
32.43
±12.86
0.122a
47.87
±16.68
Preoperative sPD-1 levels (pg/mL)
38.41
±20.41
0.088a
68.21
±26.45
Postoperative 30th day sPD-1 levels (pg/mL)
32.49
±12.42
0.185a
50.71
±19.13

17.60
±8.34
18.27
±22.36
0.291 b
28.30
±23.19
17.60
±14.85
0.015a*
39.99
±22.63
Postoperative 30th day sPD-L1 levels (pg/mL)
9.37
±7.22
9.37
±14.20
0.424 b
14.11
±10.32
9.37
±7.21
0.013a*
26.62
±16.26
Preoperative sPD-L1 levels (pg/mL)
16.76
±12.62
0.001a*
59.73
±17.27
Postoperative 30th day sPD-L1 levels (pg/mL)
9.15
±5.83
0.001a*
29.26
±15.74

a. The Mann–Whitney U test
b. The Kruskal–Wallis test
c. Dunn’s post hoc test
SD: Standard deviation, *: statistically significant

4. Discussion
Lung cancer is the most frequently diagnosed cancer type
with the highest mortality in the world [11]. Numerous
genetic and epigenetic alterations occur in all cancers,
leading to the production of a large number of antigens
in tumor cells. Thus, cancer cells are recognized by the
immune system and distinguished from normal cells
[2,11]. Remarkable advances have been achieved in cancer
immunotherapy with the discovery of various antigens
used by the immune system in recent years [7]. The
PD-1/PD-L1 pathway is one of the most useful immune
checkpoints in the treatment of cancer patients [4]. PD-L1
is also present in the cytoplasm and plasma membrane of
nonsmall cell lung cancer cells [5]. These PD-L1s interact
with PD-1, causing immunosuppression [3]. Increased
PD-L1 expression has also been shown to be associated
with poor prognosis and decreased overall survival
[6]. There are two distinct expression forms of a large
number of costimulatory molecules in immune regulatory
pathways, which are membrane-bound form and soluble
form. The measured blood levels of soluble PD-1 and
PD-L1 are useful in predicting the clinicopathological
characteristics, treatment response, and survival outcomes
of cancer patients [9].
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In their study, Okumo et al. showed significantly
higher sPD-L1 levels in advanced stage NSCLC patients
compared to the healthy control group [10]. In another
study which compared sPD-1 levels of 66 patients with
triple-negative breast cancer and 59 healthy individuals,
higher sPD-1 levels were detected in the study arm [12].
In line with the mentioned studies, our study also showed
significantly higher preoperative sPD-L1 and sPD-1 levels
in the study group.
Surgery is still the first-line treatment modality for
patients with early-stage NSCLC. However, studies have
shown that 30%–50% of patients develop recurrence
after the surgery. Thus, postoperative follow-up of these
patients is of paramount importance [13]. We measured
both preoperative sPD-1 and sPD-L1 levels in patients
who underwent surgical resection and compared these
levels with the postresection values on the 1st, 7t, and
30th days. We showed a statistically significant decrease in
both sPD-1 and sPD-L1 levels in the postoperative period.
Similarly, in a recent study conducted in 24 patients
with hepatitis B virus-associated hepatocellular cancer
and who underwent hepatobiliary surgery, researchers
demonstrated a significant decrease in sPD-1 levels
postoperatively [14]. In light of these studies, we postulate

ANCIN et al. / Turk J Med Sci
that sPD-1 and sPD-L1 levels increase in proportion to
tumor burden and can potentially be used as a marker in
the postoperative follow-up of NSCLC.
He et al. investigated the correlation between tumor size
and sPD-1 and sPD-L1 levels in 88 NSCLC patients but were
unable to find any correlation [15]. However, Frigola et al.
reported that sPD-L1 levels were associated with tumor size
in patients with renal cell cancer [16]. Our study showed a
positive correlation between the tumor size and the sPD1 levels in the preoperative and postoperative 1st month.
However, there was no significant difference between
sPD-L1 levels and tumor size measured in the same period.
It is known that there are various immunosuppression
mechanisms mediated by the PD-1/PD-L1 pathway in
the tumor microenvironment and that PD-L1 is highly
expressed by tumor cells and other cells in the tumor
microenvironment. Similarly, PD-1 is expressed by cells
in the tumor microenvironment and its soluble form is
released into the circulation [17]. In light of these data, we
believe that sPD-L1 and sPD-1 levels are increasing parallel
to the increase in tumor burden, as also observed in other
tumor markers. We think that the discrepancies between
the studies may be due to the small number of patients, the
heterogeneity of the patient groups, and the newly used
ELISA methods for the determination of soluble forms.
Okuma et al. showed no correlation between the
sPD-L1 levels and NSCLC histopathologic subtypes [18].
Consistently, our study also did not show any correlation
between the histopathological types and preoperative and
postoperative 30th day sPD-1 and sPD-L1 levels.
Cheng et al. compared sPD-L1 levels in various stages
of NSCLC and showed that sPD-L1 levels are higher in
stage 3 and 4 compared to early stages [19]. However,
Okuma et al. showed no correlation between the stage of
cancer and sPD-L1 levels in patients with advanced NSCLC
[10]. There is no study in the literature demonstrating the
correlation between the T category of the TNM staging
system and the levels of sPD-1 and sPD-L1. We think
that it would be more useful to make a comparison with
the T category instead of the stage since our study was
conducted solely on early-stage patients who underwent
surgical treatment. We showed a significant correlation
between the T category and preoperative sPD-1 levels.
The post hoc analysis revealed significantly higher sPD1 levels in T2 tumors compared to T1 tumors. Also, the
analysis of the correlation between the T category and
postoperative 30th day sPD-1 levels of the patients showed
a statistically significant difference. However, we did not
find any correlation between the T category and sPD-L1
levels. Most of the measured levels of sPD-L1 are caused
by PD-L1 found on the surface of tumor cells. Likewise,
PD-1 is expressed by cells in the tumor microenvironment
and its soluble form is released into the circulation [17]. In

view of these data, we predict a rise of sPD-L1 and sPD-1
levels in correlation with the increase in the T category.
Nevertheless, we could only observe this rise only for
certain T categories. We believe that this is due to our
insufficient sample size.
To our knowledge, there is no study in the literature
which shows the correlation between pleural invasion
and sPD-1 and sPD-L1 levels. In a study of 141 patients
with hepatitis B virus-associated hepatocellular cancer, a
correlation was found between circulating PD-L1 levels
and vascular invasion [20]. Tominaga et al. also showed
a significant association between high sPD-L1 levels
and lymphovascular invasion in patients with locally
advanced rectal cancer [21]. In our study, we observed
higher preoperative sPD-L1 levels in patients with
pleural invasion compared with those without invasion.
In addition, postoperative 30th day sPD-L1 levels were
significantly higher in patients with pleural invasion.
However, there was no significant correlation between
pleural invasion and sPD-1 levels. The soluble molecular
form of costimulatory molecules is generated by proteolytic
degradation of the membrane-bound form of proteins.
Therefore, higher serum concentrations of sPD-L1 should
be expected in patients with pleural invasion, which is also
supported with the results of our study.
The mechanisms by which malignant tumors separate
from their primary sites and metastasize to regional
lymph nodes are complex. Following tumor growth,
lymphangiogenic cytokines are released, leading to
the development of new lymphatic vessels towards the
tumor. Tumor cells migrate to lymph nodes through these
lymphatic capillaries. Angiogenesis around the tumor
occurs similarly. Cytokines that play a role in angiogenesis
and lymphangiogenesis are similar [22]. Zheng et al. found
a significant correlation between the expression level of
circulating PD-L1 and lymph node metastasis in patients
with advanced stomach cancer [23]. Our analysis also
showed that the preoperative sPD-L1 levels significantly
increased as the N category increased. However, there was
no correlation between the N categories and preoperative
sPD-1 levels of the patients. Similarly, the postoperative
30th day sPD-L1 levels measured significantly higher as
the N category increased, while the sPD-1 levels showed
no significant difference in the same period. Therefore, a
positive correlation between the levels of circulating PDL1 and the N category is expected.
Our study had limitations that should be addressed. First
of all, this study was conducted at a single center in Turkey,
which may limit generalizability of the results to larger
populations. Secondly, the sample size is relatively small.
Thirdly, the follow-up period was only 1 month; therefore,
the role of levels of circulating PD-1 and PD-L1 as a tumor
marker was difficult to analyze.
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5. Conclusion
In conclusion, our study demonstrated that sPD-1 and
sPD-L1 levels can be used as a potential biomarker for lung
cancer screening, prediction of the stage, and besides to
detect recurrences and/or metastases following resection
in NSCLC. However, our data deserve further verification
with multicenter and larger-scale prospective trials.
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